Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 2/20 | 0.67 |
| ▸ | JAK2 | O60674 | 11/20 | 0.55 |
| ▸ | JAK3 | P52333 | 9/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.55 |
| ▸ | SRC | P12931 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612697 | 0.90 | SRC (0.56) | TTKJAK2JAK3PTK2SRC | |
| SCHEMBL612559 | 0.84 | TTK (0.49) | TTKJAK2JAK3PTK2SRC | |
| SCHEMBL41292 | 0.83 | LRRK2 (0.49) | TTKJAK2JAK3PTK2SRC | |
| SCHEMBL41597 | 0.83 | LRRK2 (0.47) | TTKJAK2JAK3PTK2SRC | |
| SCHEMBL613379 | 0.83 | LRRK2 (0.47) | TTKJAK2JAK3PTK2SRC | |
| SCHEMBL612670 | 0.82 | SRC (0.45) | TTKJAK2JAK3PTK2SRC | |
| SCHEMBL1933346 | 0.81 | TTK (1.00) | TTKJAK2JAK3PTK2LRRK2 | |
| SCHEMBL41482 | 0.81 | LRRK2 (0.46) | TTKJAK2SRCLRRK2PIK3CG | |
| SCHEMBL613040 | 0.80 | LRRK2 (0.52) | TTKJAK2JAK3SRCABL1 | |
| SCHEMBL41177 | 0.80 | LRRK2 (0.46) | TTKJAK2JAK3PTK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041195-A1 | Heterocyclic compounds | FOVEA PHARMACEUTICALS | 2012-02-16 | — | — | US | claimed |
| EP-2396324-A1 | Ý1, 2, 4¨TRIAZOLO Ý1, 5 -A¨PYRIDINES AS KINASE INHIBITORS | Fovea Pharmaceuticals (FR) | 2011-12-21 | — | — | EP | claimed |
| WO-2010092041-A1 | [1, 2, 4] TRIAZOLO [1, 5 -A] PYRIDINES AS KINASE INHIBITORS | FOVEA PHARMACEUTICALS SA (FR) | 2010-08-19 | — | — | WO | claimed |
| US-20120041195-A1 | Heterocyclic compounds | FOVEA PHARMACEUTICALS | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041195-A1 | Heterocyclic compounds | MAP3K1, MAP3K5, MAP3K2 | TTK 277/4885JAK2 325/4885JAK3 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.